Considering that SMARCB1-deficient tumors exhibit clonal expansion of T-cell subsets and have higher tumor-specific immune responses, in this case report, the patient had a Tumor Proportion Score (TPS) of 30%, which is considered a moderate level of expression, and a Combined Positive Score (CPS) of 40%. The gene discussed is SMARCB1; the disease is neoplasm.